샘플 요청 목록

 카트 문의
시장보고서
상품코드
1775058

바이오의약품 CMO 및 CRO 시장

Biopharmaceutical CMO and CRO
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 372 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이오의약품 CMO 및 CRO 세계 시장은 2030년까지 459억 달러에 달할 전망

2024년에 351억 달러로 추정되는 바이오의약품 CMO 및 CRO 세계 시장은 2024-2030년 분석 기간에 CAGR 4.5%로 성장하여 2030년에는 459억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 생물학적 제제 유형은 CAGR 5.3%를 기록하며 분석 기간 종료시에는 321억 달러에 달할 것으로 예측됩니다. 바이오시밀러 의약품 성장률은 CAGR 3.0%로 추정됩니다.

미국 시장은 96억 달러, 중국은 CAGR 8.4%로 성장할 것으로 예측

미국의 바이오의약품 CMO 및 CRO 시장은 2024년에 96억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 8.4%로 성장하여 2030년에는 예측 시장 규모가 96억 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.8%와 3.6%로 예측됩니다. 유럽에서는 독일이 CAGR 2.7%로 성장할 것으로 예측됩니다.

세계의 바이오의약품 CMO 및 CRO 시장 - 주요 동향과 촉진요인 정리

바이오의약품 개발에서 아웃소싱이 중요한 이유

바이오의약품 개발이 복잡해짐에 따라 CMO(위탁생산기관) 및 CRO(위탁연구개발기관)에 아웃소싱하는 것은 전 세계 제약사들에게 필수적인 전략이 되고 있습니다. 바이오의약품과 바이오시밀러가 헬스케어 분야의 혁신을 주도하는 가운데, 전문 지식, 인프라, 규제 준수 능력에 대한 수요가 급증하고 있습니다. CMO와 CRO는 제약회사가 품질 기준을 유지하면서 연구, 임상시험, 생산을 가속화할 수 있도록 확장 가능하고 비용 효율적이며 기술적으로 진보된 솔루션을 제공합니다. 맞춤형 의료의 부상과 엄격한 규제 요건과 함께 바이오의약품 개발에서 아웃소싱의 역할이 더욱 강화되고 있습니다. 또한, COVID-19 사태는 민첩하고 유연한 제조 능력의 중요성을 부각시켰고, 백신 및 단클론항체 생산에 있어 외주업체에 대한 의존도를 높이는 결과를 초래했습니다. 기업이 업무를 간소화하고 핵심 역량에 집중하는 가운데, CMO와 CRO의 역할은 의약품 개발 기간 단축과 업무 비용 절감에 있어 더욱 두드러지고 있습니다.

기술 발전은 CMO와 CRO의 상황을 어떻게 변화시키고 있는가?

인공지능(AI), 머신러닝, 자동화 등 첨단 기술의 도입은 바이오의약품 CMO 및 CRO 시장에 혁명을 불러일으키고 있습니다. AI를 활용한 예측 분석과 첨단 바이오인포매틱스는 신약개발, 환자 모집, 임상시험의 효율성을 향상시키고 있습니다. 로봇 공학 및 연속 제조 기술은 바이오의약품 제조의 확장성과 정확성을 높이고 낭비와 운영상의 병목현상을 줄이고 있습니다. 또한, 세포 치료제 및 유전자 치료제 제조의 발전으로 최첨단 바이오프로세스 기술을 갖춘 전문 위탁 서비스 제공업체의 필요성이 증가하고 있습니다. 단클론항체, 백신, 유전자재조합치료제 등 바이오의약품이 더욱 복잡해짐에 따라 CMO와 CRO는 모듈식 생산설비, 일회용 바이오리액터, 공정 최적화를 위한 디지털 트윈 기술 등으로 역량을 확장하고 있습니다. 이러한 기술 혁신의 물결은 효율성을 높일 뿐만 아니라 진화하는 규제 프레임워크를 보다 확실하게 준수함으로써 차세대 바이오의약품의 상용화를 가속화하고 있습니다.

바이오의약품 CMO 및 CRO 서비스의 성장을 촉진하는 시장 동향은?

거시경제 및 산업별 동향이 바이오의약품 CMO 및 CRO 시장의 성장을 견인하고 있습니다. 암, 심혈관질환, 자가면역질환 등 만성질환의 유병률이 높아지면서 생물학적 제제에 대한 수요가 증가함에 따라 제약사들은 개발-제조 아웃소싱을 추진하고 있습니다. 또한, 임상시험의 세계화로 인해 여러 지역에 걸친 복잡한 규제 상황에 대응할 수 있는 CRO에 대한 수요가 급증하고 있습니다. 아시아태평양의 신흥 시장, 특히 중국과 인도는 비용 이점, 숙련된 노동력, 정부 혜택으로 인해 바이오의약품 아웃소싱의 중요한 거점이 되고 있습니다. 또 다른 큰 흐름은 CMO와 CRO 부문의 통합으로, 대기업들이 서비스 포트폴리오와 지리적 범위를 확장하기 위해 중소기업을 인수하고 있습니다. 또한, 지속가능성과 그린 케미스트리에 대한 관심이 높아지면서 바이오의약품 제조 시 폐기물 발생과 에너지 소비를 최소화하고 환경 친화적인 제조 공정을 채택하도록 위탁 생산업체에 영향을 미치고 있습니다. 이러한 요소들이 결합되어 의약품 가치사슬에서 필수적인 파트너로서 수탁 제조업체의 역할이 더욱 확고해지고 있습니다.

바이오의약품 CMO 및 CRO 시장의 성장을 촉진하는 주요 요인은 무엇인가?

바이오의약품 CMO 및 CRO 시장의 성장은 생물학적 제제에 대한 수요 증가, R&D 비용 증가, 유연하고 확장 가능한 제조 솔루션으로의 전환 등 여러 가지 요인에 의해 이루어지고 있습니다. 관류형 바이오리액터 및 일회용 시스템과 같은 바이오 공정 기술의 발전으로 위탁 제조업체는 생산 효율성을 최적화하고 시장 출시 시간을 단축할 수 있게 되었습니다. 제약사들은 약동학, 독성학, 규제 준수 등의 전문성을 확보하기 위해 초기 단계의 연구와 임상시험을 CRO에 위탁하는 사례가 늘고 있습니다. 바이오시밀러 및 희귀질환 치료제 파이프라인이 확대되면서 소규모 바이오테크놀러지 기업들이 비용 효율적이고 컴플라이언스를 준수할 수 있는 생산 솔루션을 찾고 있는 것도 위탁생산 서비스에 대한 수요를 촉진하고 있습니다. 또한, 임상시험의 분산화와 실제 데이터 분석으로의 바이오 제약 산업의 변화는 디지털 헬스 역량을 갖춘 CRO와의 파트너쉽을 촉진하고 있습니다. 기업이 속도, 민첩성, 비용 효율성을 우선시하는 가운데 CMO와 CRO의 통합 솔루션에 대한 수요는 계속 증가하여 바이오의약품 혁신과 상업화의 미래를 형성할 것으로 보입니다.

부문

제품 유형(생물학적 제제 유형, 바이오시밀러 유형), 원료 유형(포유류, 비포유류), 서비스 유형(위탁생산 서비스, 프로세스 개발 서비스, 완제 작업, 분석·QC 시험, 위탁생산 서비스)

조사 대상 기업 사례

  • AbbVie Inc.
  • Baxter International Inc.
  • Binex Co., Ltd.
  • Biothrive Sciences
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Cummins, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • FujiFilm Diosynth Biotechnologies U.S.A., Inc.
  • ICON plc
  • Jrs Pharma GmbH Co. KG
  • KBI Biopharma
  • Kemwell Biopharma Pvt., Ltd.
  • Lonza Group Ltd.
  • PAREXEL International Corporation
  • ProBioGen AG
  • Rentschler Biopharma SE
  • Samsung BioLogics Co., Ltd.
  • Sartorius AG
  • Sterling Pharma Solutions
  • Syneos Health
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi AppTec Co., Ltd.
  • WuXi Biologics

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.01

Global Biopharmaceutical CMO and CRO Market to Reach US$45.9 Billion by 2030

The global market for Biopharmaceutical CMO and CRO estimated at US$35.1 Billion in the year 2024, is expected to reach US$45.9 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Biologics Type, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$32.1 Billion by the end of the analysis period. Growth in the Biosimilars Type segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.6 Billion While China is Forecast to Grow at 8.4% CAGR

The Biopharmaceutical CMO and CRO market in the U.S. is estimated at US$9.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.6 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Biopharmaceutical CMO and CRO Market - Key Trends & Drivers Summarized

Why Is Outsourcing Becoming Critical in Biopharmaceutical Development?

The increasing complexity of biopharmaceutical development has made outsourcing to Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) an essential strategy for pharmaceutical companies worldwide. With biologics and biosimilars driving innovation in the healthcare sector, the demand for specialized expertise, infrastructure, and regulatory compliance capabilities is surging. CMOs and CROs offer scalable, cost-efficient, and technologically advanced solutions that enable pharmaceutical firms to expedite research, clinical trials, and production while maintaining quality standards. The rise of personalized medicine, coupled with stringent regulatory requirements, has further cemented the role of outsourcing in biopharmaceutical development. Additionally, the COVID-19 pandemic underscored the importance of agile and flexible manufacturing capabilities, prompting increased reliance on external contract service providers for vaccine and monoclonal antibody production. As companies continue to streamline operations and focus on core competencies, the role of CMOs and CROs in accelerating drug development timelines and reducing operational costs is becoming more pronounced.

How Are Technological Advancements Reshaping the CMO and CRO Landscape?

The adoption of cutting-edge technologies such as artificial intelligence (AI), machine learning, and automation is revolutionizing the biopharmaceutical CMO and CRO market. AI-powered predictive analytics and advanced bioinformatics are improving drug discovery, patient recruitment, and clinical trial efficiency. Robotics and continuous manufacturing techniques are enhancing the scalability and precision of biopharmaceutical production, reducing waste and operational bottlenecks. Furthermore, advancements in cell and gene therapy manufacturing have necessitated the need for specialized contract service providers equipped with state-of-the-art bioprocessing technologies. As the industry moves towards more complex biologics, including monoclonal antibodies, vaccines, and gene-modified therapies, CMOs and CROs are expanding their capabilities to include modular production facilities, single-use bioreactors, and digital twin technology for process optimization. This wave of innovation is not only increasing efficiency but also ensuring better compliance with evolving regulatory frameworks, thereby accelerating the commercialization of next-generation biopharmaceuticals.

What Market Trends Are Driving the Growth of Biopharmaceutical CMO and CRO Services?

Several macroeconomic and industry-specific trends are fueling the growth of the biopharmaceutical CMO and CRO market. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions has escalated the demand for biologics, propelling pharmaceutical firms to outsource development and production. Additionally, the globalization of clinical trials has led to a surge in demand for CROs that can navigate complex regulatory landscapes across multiple regions. Emerging markets in Asia-Pacific, particularly China and India, are becoming key hubs for biopharmaceutical outsourcing due to cost advantages, skilled labor, and government incentives. Another significant trend is the consolidation within the CMO and CRO sectors, as larger players acquire smaller firms to expand their service portfolios and geographic reach. Furthermore, the increasing focus on sustainability and green chemistry is influencing contract manufacturers to adopt eco-friendly production processes, minimizing waste generation and energy consumption in biopharmaceutical production. The convergence of these factors is solidifying the role of contract service providers as indispensable partners in the pharmaceutical value chain.

What Are the Key Drivers Fueling the Growth of the Biopharmaceutical CMO and CRO Market?

The growth in the biopharmaceutical CMO and CRO market is driven by several factors, including rising demand for biologics, increasing R&D expenditures, and the shift toward flexible and scalable manufacturing solutions. Advances in bioprocessing technologies, such as perfusion bioreactors and single-use systems, are enabling contract manufacturers to optimize production efficiency and reduce time-to-market. Pharmaceutical companies are increasingly outsourcing early-stage research and clinical trials to CROs to gain access to specialized expertise in pharmacokinetics, toxicology, and regulatory compliance. The expanding pipeline of biosimilars and orphan drugs is also driving demand for contract services, as smaller biotech firms seek cost-effective and compliant production solutions. Additionally, the biopharmaceutical industry’s shift toward decentralized clinical trials and real-world data analytics is fostering partnerships with CROs equipped with digital health capabilities. As companies prioritize speed, agility, and cost efficiency, the demand for integrated CMO and CRO solutions will continue to rise, shaping the future of biopharmaceutical innovation and commercialization.

SCOPE OF STUDY:

The report analyzes the Biopharmaceutical CMO and CRO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Biologics Type, Biosimilars Type); Source Type (Mammalian Source, Non-Mammalian Source); Service Type (Contract Manufacturing Services, Process Development Services, Fill and Finish Operations, Analytical and QC Studies, Contract Manufacturing Services)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Baxter International Inc.
  • Binex Co., Ltd.
  • Biothrive Sciences
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Cummins, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • FujiFilm Diosynth Biotechnologies U.S.A., Inc.
  • ICON plc
  • Jrs Pharma GmbH Co. KG
  • KBI Biopharma
  • Kemwell Biopharma Pvt., Ltd.
  • Lonza Group Ltd.
  • PAREXEL International Corporation
  • ProBioGen AG
  • Rentschler Biopharma SE
  • Samsung BioLogics Co., Ltd.
  • Sartorius AG
  • Sterling Pharma Solutions
  • Syneos Health
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi AppTec Co., Ltd.
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biopharmaceutical CMO and CRO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Acceleration in Biologic Drug Development Pipelines Drives Outsourcing Demand Across CDMO and CRO Functions
    • Surge in Clinical Trials for mAbs, ADCs, and Cell and Gene Therapies Throws the Spotlight on Integrated Service Providers
    • OEM Preference for End-to-End Solutions Strengthens Business Case for Full-Service Biopharma CMOs and CROs
    • Rising Biotech VC Funding and Startup Formation Spurs Demand for Flexible and Early-Phase Support Services
    • Regulatory Emphasis on cGMP Compliance and QbD Principles Drives CDMO Capability Expansion
    • Growth in Globalized Clinical Trials and Decentralized Study Models Fuels Demand for Agile CRO Partnerships
    • OEM Focus on Speed-to-Market and Risk-Sharing Engagements Propels Strategic Outsourcing Alliances
    • Emergence of Complex Modalities and Personalized Therapies Expands Need for High-Tech CDMO Infrastructure
    • Surge in Biologics Patent Expiry and Biosimilar Development Strengthens Use of CRO/CDMO Hybrid Platforms
    • Adoption of Continuous Manufacturing, Single-Use Systems, and Modular Facilities Enhances Operational Agility
    • Rising Complexity in Regulatory Submissions Encourages Biomarker-Integrated CRO Services
    • OEM Investments in Integrated Development-Manufacturing Models Promote Lifecycle Engagement Strategies
    • Expansion of CDMO Services in Viral Vector, mRNA, and Plasmid DNA Platforms Drives Modalities Diversification
    • Use of Real-World Data, eSource, and AI in Clinical Trial Design Supports Data-Rich CRO Services
    • Demand for IND-Enabling Services and Tech Transfer Expertise Strengthens Early Phase CDMO Activity
    • Growing Interest in CDMO Consolidation and Vertical Integration Supports Competitive Differentiation
    • OEM Demand for Flexible Fill-Finish Capabilities and Cold Chain Packaging Boosts CDMO Specialization
    • Strategic Partnerships With Academic Research Sites Expand CRO Access to Rare Disease and Orphan Trial Populations
    • Shifting Toward Risk-Based Monitoring and Adaptive Protocols Enhances CRO Operational Intelligence
    • Globalization of CDMO Footprints in Asia-Pacific and Eastern Europe Supports Cost-Efficient Clinical and GMP Manufacturing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biopharmaceutical CMO and CRO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biopharmaceutical CMO and CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Biopharmaceutical CMO and CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Biologics Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biosimilars Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biosimilars Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Biosimilars Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Mammalian Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Non-Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Non-Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Non-Mammalian Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Contract Manufacturing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Contract Manufacturing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Contract Manufacturing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Contract Research Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Contract Research Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Contract Research Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • JAPAN
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • CHINA
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • EUROPE
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Biopharmaceutical CMO and CRO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Biopharmaceutical CMO and CRO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • FRANCE
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • GERMANY
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Italy 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: UK 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 101: UK Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 107: Spain Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Spain Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Spain 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 116: Russia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Russia Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Russia 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Biopharmaceutical CMO and CRO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 15-Year Perspective for Biopharmaceutical CMO and CRO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 146: Australia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Australia Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Australia 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • INDIA
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 155: India Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: India Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: India 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 158: India Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 164: South Korea Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: South Korea Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: South Korea 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 173: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Asia-Pacific Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Asia-Pacific 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 182: Latin America Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 183: Latin America Historic Review for Biopharmaceutical CMO and CRO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Latin America 15-Year Perspective for Biopharmaceutical CMO and CRO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 194: Argentina Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Argentina Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Argentina 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 203: Brazil Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Brazil Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Brazil 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 212: Mexico Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Mexico Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Mexico 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 221: Rest of Latin America Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Rest of Latin America Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Rest of Latin America 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 230: Middle East Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 231: Middle East Historic Review for Biopharmaceutical CMO and CRO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Middle East 15-Year Perspective for Biopharmaceutical CMO and CRO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 242: Iran Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Iran Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Iran 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 251: Israel Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Israel Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Israel 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 260: Saudi Arabia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Saudi Arabia Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Saudi Arabia 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 269: UAE Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: UAE Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: UAE 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 278: Rest of Middle East Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Rest of Middle East Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Rest of Middle East 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030
  • AFRICA
    • Biopharmaceutical CMO and CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 287: Africa Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Africa Historic Review for Biopharmaceutical CMO and CRO by Product Type - Biologics Type and Biosimilars Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Africa 15-Year Perspective for Biopharmaceutical CMO and CRO by Product Type - Percentage Breakdown of Value Sales for Biologics Type and Biosimilars Type for the Years 2015, 2025 & 2030
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Biopharmaceutical CMO and CRO by Source Type - Mammalian Source and Non-Mammalian Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Biopharmaceutical CMO and CRO by Source Type - Percentage Breakdown of Value Sales for Mammalian Source and Non-Mammalian Source for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Biopharmaceutical CMO and CRO by Service Type - Contract Manufacturing Services and Contract Research Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Biopharmaceutical CMO and CRO by Service Type - Percentage Breakdown of Value Sales for Contract Manufacturing Services and Contract Research Services for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제